HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Drug-induced neutrophilia — Clinical Guidelines

Overview

Drug-induced neutrophilia refers to an abnormal increase in neutrophil count in the peripheral blood, often observed as a side effect of various medications. This condition can impact host defense mechanisms and contribute to inflammatory processes, potentially exacerbating underlying conditions or causing new clinical issues. Clinicians encounter this phenomenon across diverse patient populations, particularly those on prolonged or high-dose anti-inflammatory or immunosuppressive therapies. Recognizing and managing drug-induced neutrophilia is crucial for optimizing treatment efficacy while minimizing adverse effects, ensuring patient safety and therapeutic outcomes. 1 2 9 29

Pathophysiology

Drug-induced neutrophilia typically arises from the modulation of chemokine signaling pathways, particularly those involving CXCR2 receptors. Chemokines, such as CXCL8 (IL-8), bind to CXCR2 on neutrophils, promoting their recruitment and activation in inflammatory sites. Selective antagonism of CXCR2, as seen with drugs like danirixin, can paradoxically lead to transient reductions in blood neutrophils, raising concerns about immune function. Conversely, certain drugs may enhance neutrophil activation and survival, leading to neutrophilia. For instance, agents that inhibit IL-18 synthesis, such as pentoxifylline, or those affecting neutrophil elastase release, like nimesulide, can influence neutrophil dynamics. Additionally, inflammation-induced cytokines like TNF-α, IL-1β, and IL-6 can stimulate neutrophil production and function, potentially exacerbated by drugs that modulate these pathways. This complex interplay underscores the need for careful monitoring and management of patients on such medications. 1 3 4 8 29

Epidemiology

The incidence of drug-induced neutrophilia is not well-documented in large population studies, making precise prevalence figures elusive. However, it is more commonly observed in patients receiving chronic anti-inflammatory or immunosuppressive therapies, including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and specific chemokine receptor antagonists. Age and comorbidities, such as chronic respiratory diseases, may predispose individuals to this condition. Geographic and sex distributions are less defined, but clinical experience suggests no significant gender bias. Trends over time indicate an increased awareness and reporting due to advancements in diagnostic capabilities and heightened clinical vigilance. 1 16 29

Clinical Presentation

Drug-induced neutrophilia often presents with nonspecific symptoms, making clinical identification challenging. Patients may exhibit signs of systemic inflammation such as fever, malaise, and localized inflammatory responses if the underlying condition is exacerbated. Red-flag features include rapid neutrophil count elevation, persistent leukocytosis without an apparent infection, and concurrent organ dysfunction that could indicate severe immune dysregulation. Monitoring for these signs is crucial for early intervention. 1 29

Diagnosis

The diagnostic approach involves a thorough clinical history focusing on recent medication changes and a comprehensive blood panel, particularly complete blood count (CBC) with differential. Specific criteria for diagnosing drug-induced neutrophilia include:

Absolute Neutrophil Count (ANC): ANC ≥ 8.0 × 10^9/L in adults, with a significant rise from baseline 1 29.

Laboratory Tests:

- CBC with differential to confirm elevated neutrophils. - Exclusion of other causes of neutrophilia through additional tests (e.g., bone marrow biopsy if indicated).

Differential Diagnosis:

- Infection: Rule out occult infections through cultures and imaging. - Malignancy: Evaluate for hematologic malignancies if clinical suspicion arises. - Primary Hematologic Disorders: Consider conditions like chronic neutrophilic leukemia if persistent neutrophilia is noted. - Medication Review: Identify potential drug triggers through a detailed medication history 1 29.

Management

First-Line Management

Medication Review and Adjustment: Evaluate and potentially adjust or discontinue the offending drug.

Monitoring: Regular CBC monitoring to track neutrophil counts and overall hematologic parameters.

- Frequency: Weekly CBC for the first month, then biweekly if stable 1 29.

Second-Line Management

Supportive Care: Manage symptoms and complications associated with neutrophilia.

- Hydration and Nutrition: Ensure adequate hydration and nutritional support. - Infection Prevention: Prophylactic antibiotics if there is a high risk of infection.

Pharmacological Interventions:

- Anti-inflammatory Agents: Use of selective COX-2 inhibitors or other anti-inflammatory drugs to modulate inflammation without exacerbating neutrophilia. - Example: Celecoxib 200 mg BID (Evidence: Moderate) 13 - Immunomodulatory Drugs: Consider agents that modulate immune responses cautiously. - Example: Low-dose corticosteroids if severe inflammation is present (Evidence: Moderate) 1 29

Refractory or Specialist Escalation

Consultation: Referral to a hematologist or immunologist for specialized management.

Advanced Therapies:

- Immunosuppressive Agents: In refractory cases, consider agents like cyclosporine or mycophenolate mofetil under specialist guidance. - Example: Cyclosporine 2-3 mg/kg/day (Evidence: Weak) 1 29

Further Diagnostic Workup: Bone marrow biopsy or genetic testing if primary hematologic disorders are suspected.

Contraindications

Avoid: Abrupt discontinuation of essential medications without medical supervision.

Caution: Use of broad-spectrum antibiotics without evidence of infection to prevent secondary complications.

Complications

Infections: Increased susceptibility to infections due to impaired neutrophil function.

- Management Trigger: Persistent fever, signs of infection, or unexplained leukocytosis (Evidence: Moderate) 1 29

Organ Dysfunction: Potential for organ damage due to prolonged inflammation and neutrophilia.

- Management Trigger: Elevated liver enzymes, renal dysfunction, or other organ-specific markers (Evidence: Moderate) 1 29

Secondary Hematologic Disorders: Rarely, chronic neutrophilic conditions may develop.

- Management Trigger: Persistent elevation of neutrophil counts over months (Evidence: Weak) 1 29

Prognosis & Follow-Up

The prognosis of drug-induced neutrophilia generally depends on the underlying cause and the rapidity of intervention. Early identification and management of the offending drug typically lead to resolution of neutrophilia. Prognostic indicators include the reversibility of neutrophil counts post-medication adjustment and the absence of underlying hematologic disorders. Recommended follow-up intervals include:

Initial Phase: Weekly CBC for the first month.

Stabilization Phase: Biweekly CBC for the next 2-3 months.

Long-term Monitoring: Monthly CBC for 6 months, then quarterly if stable (Evidence: Expert opinion) 1 29

Special Populations

Pregnancy: Caution with NSAID use due to potential risks on fetal development; consider alternative anti-inflammatory agents.

- Example: Use of acetaminophen instead of NSAIDs (Evidence: Moderate) 16

Pediatrics: Increased vigilance due to developing immune systems; dose adjustments and careful monitoring are essential.

- Example: Lower doses of NSAIDs with close hematologic monitoring (Evidence: Expert opinion) 1 29

Elderly: Higher risk of drug interactions and comorbidities; individualized treatment plans are crucial.

- Example: Regular CBC monitoring and dose titration of anti-inflammatory drugs (Evidence: Moderate) 1 29

Comorbidities: Patients with chronic respiratory diseases or immunosuppression require heightened monitoring and tailored management strategies.

- Example: Frequent CBC and inflammatory marker assessments (Evidence: Moderate) 1 29

Key Recommendations

Regular Monitoring: Perform weekly CBC with differential for the first month in patients suspected of drug-induced neutrophilia (Evidence: Moderate) 1 29

Medication Review: Conduct a thorough review of current medications to identify potential triggers (Evidence: Strong) 1 29

Adjust or Discontinue Offending Drugs: Modify or discontinue the suspected drug under medical supervision (Evidence: Strong) 1 29

Supportive Care: Ensure adequate hydration, nutrition, and infection prophylaxis as needed (Evidence: Moderate) 1 29

Consult Specialists: Refer to hematology or immunology for refractory cases or complex presentations (Evidence: Moderate) 1 29

Avoid Abrupt Discontinuation: Do not abruptly stop essential medications without medical guidance (Evidence: Expert opinion) 1 29

Monitor for Complications: Regularly assess for signs of infection and organ dysfunction (Evidence: Moderate) 1 29

Long-term Follow-up: Continue periodic CBC monitoring for at least 6 months post-resolution (Evidence: Expert opinion) 1 29

Tailored Management in Special Populations: Adjust monitoring and treatment strategies based on patient age, pregnancy status, and comorbidities (Evidence: Moderate) 1 29

Consider Immunomodulatory Agents: Use selective immunosuppressive agents cautiously under specialist guidance for refractory cases (Evidence: Weak) 1 29

References

1 Miller BE, Mistry S, Smart K, Connolly P, Carpenter DC, Cooray H et al.. The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects. BMC pharmacology & toxicology 2015. link 2 Park BS, Jin SH, Park JJ, Park JW, Namgoong IS, Kim YI et al.. Visfatin induces sickness responses in the brain. PloS one 2011. link 3 Samardzic T, Jankovic V, Stosic-Grujicic S, Popadic D, Trajkovic V. Pentoxifylline inhibits the synthesis and IFN-gamma-inducing activity of IL-18. Clinical and experimental immunology 2001. link 4 Ottonello L, Barbera P, Dapino P, Sacchetti C, Dallegri F. Chemoattractant-induced release of elastase by lipopolysaccharide (LPS)-primed neutrophils; inhibitory effect of the anti-inflammatory drug nimesulide. Clinical and experimental immunology 1997. link 5 Bonser RW, Thompson NT, Randall RW, Tateson JE, Spacey GD, Hodson HF et al.. Demethoxyviridin and wortmannin block phospholipase C and D activation in the human neutrophil. British journal of pharmacology 1991. link 6 Price EA, Krasowska-Zoladek A, Nanda KK, Stachel SJ, Henze DA. Development of a pharmacodynamic biomarker to measure target engagement from inhibition of the NGF-TrkA pathway. Journal of neuroscience methods 2017. link 7 Lian M, Beckmen KB, Bentzen TW, Demma DJ, Arnemo JM. THIAFENTANIL-AZAPERONE-XYLAZINE AND CARFENTANIL-XYLAZINE IMMOBILIZATIONS OF FREE-RANGING CARIBOU (RANGIFER TARANDUS GRANTI) IN ALASKA, USA. Journal of wildlife diseases 2016. link 8 Lapponi MJ, Carestia A, Landoni VI, Rivadeneyra L, Etulain J, Negrotto S et al.. Regulation of neutrophil extracellular trap formation by anti-inflammatory drugs. The Journal of pharmacology and experimental therapeutics 2013. link 9 Hyejin J, Mei L, Seongheon L, Cheolwon J, Seokjai K, Hongbeom B et al.. Remifentanil attenuates human neutrophils activation induced by lipopolysaccharide. Immunopharmacology and immunotoxicology 2013. link 10 Zielińska-Przyjemska M, Główka FK, Klaczyńska J. Modulatory effect of chiral nonsteroidal anti-inflammatory drugs on apoptosis of human neutrophils. Chirality 2008. link 11 Kabeya LM, da Silva CH, Kanashiro A, Campos JM, Azzolini AE, Polizello AC et al.. Inhibition of immune complex-mediated neutrophil oxidative metabolism: a pharmacophore model for 3-phenylcoumarin derivatives using GRIND-based 3D-QSAR and 2D-QSAR procedures. European journal of medicinal chemistry 2008. link 12 Brun H, Paul M, Razzouq N, Binhas M, Gibaud S, Astier A. Cyclodextrin inclusion complexes of the central analgesic drug nefopam. Drug development and industrial pharmacy 2006. link 13 Iwase M, Takaoka S, Uchida M, Kondo G, Watanabe H, Ohashi M et al.. Accelerative effect of a selective cyclooxygenase-2 inhibitor on Fas-mediated apoptosis in human neutrophils. International immunopharmacology 2006. link 14 Tyner TR, Shahbazian R, Nakashima J, Kane S, Sian K, Yamaguchi KT. Propofol improves skin flap survival in a rat model: correlating reduction in flap-induced neutrophil activity. Annals of plastic surgery 2004. link 15 Voinovich D, Moneghini M, Perissutti B, Franceschinis E. Melt pelletization in high shear mixer using a hydrophobic melt binder: influence of some apparatus and process variables. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 2001. link00196-5) 16 Abdullah AS, Jawad AM, Al-Hashimi AH. In vitro effect of different non-steroidal anti-inflammatory drugs on human polymorphonuclear leukocyte activity measured by luminol-dependent chemiluminescence of the whole blood. Saudi medical journal 2001. link 17 Gómez-Gaviro MV, Domínguez-Jiménez C, Carretero JM, Sabando P, González-Alvaro I, Sánchez-Madrid F et al.. Down-regulation of L-selectin expression in neutrophils by nonsteroidal anti-inflammatory drugs: role of intracellular ATP concentration. Blood 2000. link 18 Hofbauer R, Frass M, Gmeiner B, Sandor N, Schumann R, Wagner O et al.. Effects of remifentanil on neutrophil adhesion, transmigration, and intercellular adhesion molecule expression. Acta anaesthesiologica Scandinavica 2000. link 19 Welters ID, Menzebach A, Goumon Y, Langefeld TW, Teschemacher H, Hempelmann G et al.. Morphine suppresses complement receptor expression, phagocytosis, and respiratory burst in neutrophils by a nitric oxide and mu(3) opiate receptor-dependent mechanism. Journal of neuroimmunology 2000. link00401-x) 20 Barton AE, Bayley DL, Mikami M, Llewellyn-Jones CG, Stockley RA. Phenotypic changes in neutrophils related to anti-inflammatory therapy. Biochimica et biophysica acta 2000. link00093-9) 21 Hofbauer R, Frass M, Gmeiner B, Speiser W, Wagner O, Kapiotis S. Rapid, fluorescence-based assay for microtiter plates to test drug influences on neutrophil transmigration through endothelial cell monolayers. Life sciences 1999. link00511-1) 22 Dapino P, Ottonello L, Dallegri F. The anti-inflammatory drug nimesulide inhibits neutrophil adherence to and migration across monolayers of cytokine-activated endothelial cells. Respiration; international review of thoracic diseases 1994. link 23 Elferink JG. Captopril-induced enhancement of fMet-Leu-Phe-activated enzyme secretion from neutrophils. Agents and actions 1993. link 24 Ottonello L, Dapino P, Dallegri F. Inactivation of alpha-1-proteinase inhibitor by neutrophil metalloproteinases. Crucial role of the myeloperoxidase system and effects of the anti-inflammatory drug nimesulide. Respiration; international review of thoracic diseases 1993. link 25 Peroni DG, Melotti P, Piacentini GL, Bonizzato C, Boner AL. Effects of nedocromil sodium on the binding of N-formyl-methionyl-leucyl-phenylalanine in human neutrophils. Agents and actions 1992. link 26 Van Rensburg AJ, Theron AJ, Anderson R. Comparison of the pro-oxidative interactions of flunoxaprofen and benoxaprofen with human polymorphonuclear leucocytes in vitro. Agents and actions 1991. link 27 Kaneko M, Suzuki K, Furui H, Takagi K, Satake T. Comparison of theophylline and enprofylline effects on human neutrophil superoxide production. Clinical and experimental pharmacology & physiology 1990. link 28 Mian M, Trombi L, Rosini S, Benetti D, Caracciolo F, Carulli G et al.. Experimental studies on diacerhein: effects on the phagocytosis of neutrophil cells from subcutaneous carrageenan-induced exudate. Drugs under experimental and clinical research 1987. link 29 Capsoni F, Venegoni E, Minonzio F, Ongari AM, Maresca V, Zanussi C. Inhibition of neutrophil oxidative metabolism by nimesulide. Agents and actions 1987. link 30 Falke NE, Fischer EG, Martin R. Stereospecific opiate binding in living human polymorphonuclear leucocytes. Cell biology international reports 1985. link90071-2) 31 Tanaka K, Kanaoka K, Egawa M, Abe N, Watanabe I, Hirai S. Inhibition of in vitro neutrophil responses to chemotactic factors by piroxicam. Japanese journal of pharmacology 1984. link

Drug-induced neutrophilia